{{Rsnum
|rsid=8904
|Gene=NFKBIA
|Chromosome=14
|position=35402011
|Orientation=minus
|GMAF=0.4233
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=NFKBIA
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 38.4 | 45.5 | 16.1
| HCB | 35.0 | 48.9 | 16.1
| JPT | 52.2 | 40.7 | 7.1
| YRI | 8.8 | 44.9 | 46.3
| ASW | 24.6 | 45.6 | 29.8
| CHB | 35.0 | 48.9 | 16.1
| CHD | 35.8 | 44.0 | 20.2
| GIH | 36.6 | 50.5 | 12.9
| LWK | 16.4 | 51.8 | 31.8
| MEX | 43.1 | 46.6 | 10.3
| MKK | 20.5 | 49.4 | 30.1
| TSI | 37.3 | 48.0 | 14.7
| HapMapRevision=28
}}{{PMID Auto
|PMID=19773451
|Title=Role of inflammation gene polymorphisms on pain severity in lung cancer patients
|OA=1
}}

{{PharmGKB
|RSID=rs8904
|Name_s=NFKBIA Ex6+50C>T
|Gene_s=NFKBIA
|Feature=3' UTR
|Evidence=PubMed ID:19773451
|Annotation=Risk or phenotype-associated allele: C. Phenotype: The CC genotype was associated with lower risk for severe pain. Study size: 667. Study population/ethnicity: Non-hispanic Caucasian patients with lung neoplasms, Texas; M. D. Anderson Cancer Center. Significance metric(s): OR = 0.64 (0.43-0.93); p = 0.02. Type of association: CO.
|Drugs=
|Drug Classes=
|Diseases=Pain
|Curation Level=Curated
|PharmGKB Accession ID=PA165349771
}}

{{PMID Auto
|PMID=16380906
|Title=Genomewide high-density SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p.
|OA=1
}}

{{PMID Auto
|PMID=18635889
|Title=Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis.
|OA=1
}}

{{PMID Auto
|PMID=19223558
|Title=Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma.
|OA=1
}}

{{PMID Auto
|PMID=19500386
|Title=Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.
|OA=1
}}

{{PMID Auto
|PMID=20811626
|Title=Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs8904
|overall_frequency_n=4779
|overall_frequency_d=10758
|overall_frequency=0.444228
|n_genomes=40
|n_genomes_annotated=0
|n_haplomes=53
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23176038
|Title=Evaluation of NFKB1A variants in patients with knee osteoarthritis.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}